Focal adhesion kinase inhibitors in fibrotic diseases therapy: Development and therapeutic potential

Area of Science:

• Biochemistry
• Pharmacology
• Pathology

Background:

• Organ fibrosis involves abnormal tissue repair and extracellular matrix deposition, posing a significant medical challenge.
• Current treatments for pulmonary fibrosis exist, but hepatic, cardiac, and renal fibrosis lack effective therapies.
• Focal adhesion kinase (FAK) plays a crucial role in the pathogenesis of organ fibrosis.

Purpose of the Study:

• To comprehensively analyze FAK's biological functions in fibrotic progression.
• To review preclinical advancements in FAK inhibitor development for organ fibrosis.
• To propose strategic frameworks for developing novel FAK-targeting drugs for fibrosis treatment.

Main Methods:

• Review of scientific literature on FAK's role in fibrosis.
• Analysis of FAK inhibitor classification based on binding patterns, pharmacodynamic efficacy, and selectivity.
• Examination of preclinical data for FAK inhibitors.

Main Results:

• FAK kinase inhibition is a pivotal therapeutic strategy for fibrosis modulation.
• Detailed classification of existing FAK inhibitors from a pharmaceutical chemistry perspective.
• Identification of potential challenges in FAK inhibitor drug development.

Conclusions:

• FAK inhibitors represent a promising therapeutic avenue for various organ fibroses.
• Understanding FAK inhibitor profiles is essential for guiding future drug development.
• Strategic development of novel FAK inhibitors can address unmet needs in fibrosis treatment.